Immune-checkpoint-blockade (ICB)-mediated rejuvenation of exhausted T cells has emerged as a promising approach for treating various cancers and chronic infections. However, T cells that become fully exhausted during prolonged antigen exposure remain refractory to ICB-mediated rejuvenation. We report that blocking de novo DNA methylation in activated CD8 T cells allows them to retain their effector functions despite chronic stimulation during a persistent viral infection. Whole-genome bisulfite sequencing of antigen-specific murine CD8 T cells at the effector and exhaustion stages of an immune response identified progressively acquired heritable de novo methylation programs that restrict T cell expansion and clonal diversity during PD-1 blockade treatment. Moreover, these exhaustion-associated DNA-methylation programs were acquired in tumorinfiltrating PD-1hi CD8 T cells, and approaches to reverse these programs improved T cell responses and tumor control during ICB. These data establish de novo DNA-methylation programming as a regulator of T cell exhaustion and barrier of ICB-mediated T cell rejuvenation.
INTRODUCTION
Antigen-driven clonal expansion and differentiation of naive CD8 T cells initially instills the cells with an effector program that facilitates their ability to directly and indirectly kill antigen-presenting cells (Kaech and Cui, 2012) . However, prolonged stimulation of the cells, as occurs during chronic infection and cancer, results in a progressive suppression of the cell's effector function, commonly referred to as ''exhaustion'' (Wherry, 2011) . During acquisition of the exhausted state, T cell functional impairment follows a hierarchical loss in expression of the effector cytokines interleukin-2 (IL-2), tumor necrosis factor alpha (TNFa), and interferon g (IFNg). Accompanying the impairment in cytokine expression is a decline in the cells' cytolytic ability, proliferative capacity, and sustained upregulated expression of surface inhibitory receptors (IRs), including programmed cell death 1 (PD-1) (Wherry, 2011) . The discovery that IRs serve as an immune checkpoint regulating T cell effector function was rapidly translated into therapeutic approaches that block these checkpoints for the treatment of various cancers (Sharma and Allison, 2015a) .
While immune-checkpoint blockade (ICB) therapy has yielded striking clinical responses, its success is unfortunately limited to a minority of patients with cancer (Sharma and Allison, 2015a) . The mechanism(s) underlying ICB therapy non-responsiveness remains a major challenge for a broader success of this therapy. Recent efforts to identify antigen-specific CD8 T cells that retain the potential to respond to ICB therapy have established that the cumulative expression of multiple inhibitory receptors progressively restricts the cells' ability to be rejuvenated (Jin et al., 2010) . Commensurate with the progressive upregulation of IRs and reduced responsiveness to ICB therapy, it has become evident that aspects of the T cell exhaustion gene-expression program are reinforced, resulting in stable maintenance of exhaustion-associated features even if the antigen levels are reduced or cleared (Angelosanto et al., 2012; Utzschneider et al., 2013; Youngblood et al., 2011) .
Given that exhaustion-associated gene expression programs can be maintained in the absence of antigen, we sought to better understand the heritable nature of T cell-intrinsic transcriptional programming and how it impacts ICB therapy. During cellular differentiation, recruitment and/or eviction of specific transcription factors to regions of accessible chromatin facilitate cell-typespecific gene expression programming (Vaquerizas et al., 2009 ). Long-term maintenance of transcription factor accessibility to gene regulatory elements is controlled in part by covalent modifications to histones and DNA that affect chromatin structure, resulting in an ''epigenetic memory'' of gene expression programs in a dividing population of cells (Bintu et al., 2016; Bird, 2002) . Consistent with prior reports showing that exhaustion-associated gene expression programs become reinforced, a recent study reported that T cell exhaustion is associated with a general increase in chromatin accessibility and that many of these accessible regions are retained after PD-1 blockade therapy (Pauken et al., 2016) . While a variety of transcription factors and epigenetic modifications are associated with changes in chromatin accessibility, recent evidence supports the notion that DNA methylation is a critical epigenetic mechanism for establishing stable gene-silencing programs (Bintu et al., 2016; Cedar and Bergman, 2009 ). We report here that de novo DNA methylation acquired during and after the peak of an effector CD8 T cell response to a chronic viral infection or tumor challenge is critical for establishing T cell exhaustion. Our study identifies genome-wide de novo DNAmethylation programs that promote terminal differentiation of exhausted T cells and reveals that these programs persist after PD-1 blockade therapy. In contrast, CD8 T cells lacking the acquisition of such methylation programs resist functional exhaustion and retain a greater potential for expansion after ICB. These data establish Dnmt3a-mediated de novo DNA methylation as a mechanism restricting the efficacy of ICB therapy and have broad implications for novel approaches to enhance T cell-based immunotherapies.
RESULTS

Post-effector De Novo DNA-Methylation Programming Accompanies T cell Exhaustion
Recent studies demonstrated that the phenotypic and functional changes that occur during the naive-to-effector stage of CD8 T cell differentiation are accompanied by genome-wide changes in DNA-methylation programming (Scharer et al., 2013) ; however, the role of these changes in regulating the functional state of the cell is largely unknown. To determine if T cell posteffector adaptation is also accompanied by additional epigenetic modifications and to assess the consequence of these epigenetic programs on the development of T cell exhaustion, we measured the quantity and function of antigen-specific wild-type (WT) or mutant CD8 T cells that lack the ability to acquire de novo DNA-methylation programs during persistent LCMV (lymphocytic choriomeningitis virus) infection in mice. Inhibition of de novo methylation programming was achieved by conditionally deleting the de novo DNA methyltransferase Dnmt3a (Dnmt3a-cKO; hereafter referred to as cKO mice) using a Cre recombinase under the control of the granzyme b promoter (Figures S1A and S1B). WT and cKO mice were initially depleted of CD4 T cells and then infected with the chronic strain of LCMV ( Figures 1A and 1B) . Longitudinal tracking of virus-specific CD8 T cells in the blood of chronically infected WT mice revealed a progressive decline in gp33-specific (a dominant LCMV epitope) CD8 T cells ( Figure 1C ) as well as a reduction in the total quantity of polyclonal LCMV-specific CD8 T cells ( Figure S1C ). In contrast, the contraction of virus-specific cKO CD8 T cells after the peak of the effector response was modest, and the quantity of cKO virus-specific CD8 T cells that survived the contraction stage of the immune response was maintained at a much greater level relative to the WT CD8 T cells ( Figures 1C and S1C) . We next assessed whether the retained cKO CD8 T cells also maintained their effector function despite persistent antigen exposure and maintenance of elevated expression of PD-1 (Figures S1E and S1G). As expected, WT antigen-specific CD8 T cells isolated from mice after 2 months of chronic infection were severely impaired in their ability to produce IFNg and IL-2 in response to peptide stimulation ( Figure 1D ). In contrast, cKO CD8 T cells retained a substantial capacity to co-produce both cytokines ( Figures 1D and S1F ). Thus, CD8 T cells lacking the ability to acquire new DNA-methylation programs retain a heightened capacity to recall effector cytokines despite prolonged TCR (T cell receptor) stimulation and sustained PD-1 expression.
To identify de novo DNA-methylation programs associated with progressive commitment to T cell exhaustion, we next measured genome-wide DNA-methylation changes in WT and cKO virus-specific CD8 T cells at the effector (8 days post-infection [dpi]; Figure S1H ) and exhaustion (35 dpi) stages of the immune response ( Figure 1E ). Initial assessment of 5' Cytosinephosphate-Guanine 3' (CpG) methylation levels across the entire genome of all samples demonstrated that differentiation of both WT and cKO day 8 antigen-specific effector CD8 T cells was coupled to $10,000 demethylated regions relative to naive CD8 T cells (Figures S1I and S1J) . In addition to DNA demethylation, WT CD8 T cells acquired $980 de novo programs, the majority of which were not acquired in the cKO effector CD8 T cells (Figures 1F and S1K) . We next examined both DNA demethylation and de novo methylation events in WT CD8 T cells during the effector-to-exhaustion stage of T cell development. In contrast to the striking level of DNA demethylation that occurred during the effector stage of the immune response, only 280 additionally demethylated regions were detected ( Figure S1J ). Moreover, we found that WT CD8 T cells acquired an additional 1,200 Dnmt3a-dependent DNA methylation events during the effectorto-exhaustion transition ( Figure 1F ). These data indicate that, during the effector-to-exhaustion transition, WT CD8 T cells continue to undergo epigenetic changes that are predominantly de novo events. To further characterize when WT and Dnmt3a cKO CD8 T cells acquire divergent DNA-methylation programs, we performed an unsupervised principle-component analysis (PCA) and generated a dendrogram of the whole-genome bisulfite sequencing (WGBS) datasets based on the methylation status of the top 3,000 most variable CpG sites in all WT and cKO (D) Representative FACS analysis of PD-1 expression on gp33-specific CD8 T cells from the spleens of WT and cKO mice after 2 months of chronic infection, gated on CD8+ T cells. Representative intracellular FACS analysis of IFNg and IL-2 expression from gp33 peptide-stimulated CD44 hi CD8 T cell splenocytes of chronically infected WT and cKO mice. (E) Experimental setup for performing whole-genome bisulfite sequencing (WGBS) methylation analysis of virus-specific CD8 T cells. (F) The number of newly methylated regions in gp33-specific effector or exhausted WT CD8 T cells. (G) Heatmap showing cluster analysis of the top 3,000 differentially methylated regions (DMRs) among naive and LCMV-specific WT and cKO CD8 T cells at the effector and chronic stages of the immune response. Color intensity scales from red (methylated region) to blue (non-methylated region antigen-specific CD8 T cells. Our analysis revealed that the DNAmethylation status of WT CD8 T cells segregated from the methylation status of cKO CD8 T cells during the effector-toexhaustion transition ( Figure S1L ). Importantly, we found that several of the chronic-associated de novo epigenetic events were acquired at sites that were initially methylated in naive CD8 T cells ( Figure 1G ). We next performed a gene ontology (GO) biological process analysis of the exhaustion-associated Dnmt3a-targeted loci to determine if Dnmt3a-targeted genes were involved in biological processes known to be impacted during T cell exhaustion. Importantly, the analysis of Dnmt3a-targets in exhausted WT CD8 T cells identified several immune-related functions among the top-ranked GO biological processes ( Figure S1M ). In addition, Biocarta pathway enrichment analysis of all Dnmt3a-targets showed statistical enrichment of immune-related signaling pathways, such as TCR-signaling and IL-7/IL-2-signaling pathways ( Figure S1N ). We further characterized these de novo programs using ingenuity-pathway analysis and observed that several transcription factors and signaling molecules, known to regulate immune-related pathways, were identified as putative regulators of the Dnmt3a-targeted loci ( Figure 1H ). Specifically among the list of Dnmt3a-targeted loci were IFNg, Myc ( Figure 1I ), Tcf7, Ccr7, Tbx21, and Eomesodermin (Eomes) ( Figure S2A ). These data document the DNA-methylation programs acquired during and after the peak of the effector response that are coupled to the progressive decline in CD8 T cell effector functions.
Chronic T Cell Stimulation Induces Post-effector De Novo DNA-Methylation Programming Our data demonstrate that de novo DNA-methylation programs are progressively acquired during the development of T cell exhaustion and that specific differentially methylated regions (DMRs) serve as an epigenetic signature for exhausted T cells. However, it is unclear whether these post-effector DNA-methylation programs are acquired due to persistent stimulation or whether they are acquired due to a hard-wired differentiation program that continues regardless of additional TCR stimulation. Therefore, we next sought to examine whether exhaustion-associated de novo DNA-methylation programs were also acquired in highly functional WT memory CD8 T cells generated during an acute viral infection. We designed loci-specific bisulfite sequencing primers to assess the methylation status of an exhaustion-associated DMR in the IFNg locus in naive and virus-specific CD8 T cells isolated from chronically infected and infection-matched immune WT and cKO mice (Figure 2A ). Both memory T cells from immune mice and cKO CD8 T cells from chronically infected mice retain high expression of IFNg (Figure 2B) , and accordingly remained demethylated at the IFNg DMR, while only WT exhausted T cells from chronically infected animals remethylated this region ( Figures 2C and S2B) . Thus, acquisition of the post-effector de novo DNA-methylation program at the IFNg locus is not simply due to slow accumulation of DNA-methylation marks over time in the aged cells, rather it results from chronic stimulation. We next asked if naive and memory-associated genes that are downregulated during the effector stage of the immune response acquire and maintain de novo DNA methylation under conditions of persistent antigen stimulation. To do this, we measured the methylation level of the DMR in the Ccr7 locus in naive and virus-specific WT and cKO CD8 T cells isolated 8 dpi (effector cells) and 60 dpi from chronic LCMV-infected mice and compared it to that of functional memory WT CD8 T cells isolated 60 dpi from acute-infected mice. Indeed, downregulation of CCR7 in effector (at 8 dpi) CD8 T cells accompanied de novo methylation of the locus ( Figure S2B ). Functional-memory cells had a reduction in this de novo program consistent with a subset of functional-memory CD8 T cells expressing CCR7. However, the Ccr7 effector-associated DMR underwent further methylation in the exhausted WT cells ( Figures 2D and S2B ). These data suggest that the transcriptional repression of genes during the effector stage of the immune response may become epigenetically reinforced during or shortly after the effector stage.
To more broadly define the de novo DNA methylation programs that are unique to T cell exhaustion, we performed WGBS methylation profiling of WT memory CD8 T cells isolated 35 days after acute LCMV infection and compared the methylation profile with the profile of exhausted WT CD8 T cells to identify DMRs. Importantly, more than 71% of the unmethylated DMRs in functional memory WT CD8 T cells relative to exhausted WT CD8 T cells were also identified as Dnmt3a-targets in exhausted cells (e.g., IFNg and Ccr7 loci) ( Figures 2E, 2F , S3A, and S3B). We next asked whether these programs are only acquired in the absence of CD4 T cell help. Interestingly, we found that even in the presence of CD4 T cell help, WT exhausted CD8 T cells still acquire similarly high levels of DNA methylation at several of these regions ( Figure S3C ). Taken together, the lack of exhaustion-associated de novo methylation programs at a genome-wide level in functional memory CD8 T cells further suggests that these programs result from the chronic stimulation of exhausted T cells.
De Novo DNA-Methylation Programming Regulates Development of Fully Exhausted T Cells Progressive adaptation of antigen-specific CD8 T cells to chronic stimulation occurs asynchronously among the total (legend continued on next page) pool of antigen-experienced cells and results in heterogeneous populations of CD8 T cells with varying degrees of T cell exhaustion. Coupled to this adaptation is the differential expression of the T-box transcription factors T-bet and Eomes (Speiser et al., 2014; Wherry, 2011) . In line with these prior findings, we identified exhaustion-associated de novo programs in the T-bet and Eomes loci among our WGBS data ( Figures S4A and  S2A ). Correspondingly, Dnmt3a-deficient CD8 T cells had significantly higher T-bet and lower Eomes expression compared to the levels observed in exhausted WT cells ( Figures S4C and  S4D ). Furthermore, the Eomes lo cells were predominantly Tim-3 -and T-bet + ( Figures S4C, S4E , and S4F). Recent studies have also linked Tcf7 expression to retention of T cell function during chronic infection (Im et al., 2016; Utzschneider et al., 2016) . Consistent with these reports, we identified an effectorassociated de novo DNA-methylation program in the Tcf7 locus ( Figure S2A ). Loci-specific methylation analysis of the Tcf7 DMR in virus-specific CD8 T cells isolated from chronically infected WT and cKO mice demonstrated that exhausted WT cells retained the repressive program acquired during the effector stage of the immune response ( Figure S4B ), whereas cKO cells retained an unmethylated Tcf7-DMR and expressed significantly higher levels of Tcf1 ( Figures S4G and S4H ). Together, these data further support a model whereby de novo DNA methylation serves as a mechanism for stable epigenetic gene silencing and reinforces commitment to terminal differentiation of exhausted T cells.
Exhaustion-Associated De Novo Methylation
Programming Is Coupled to the Limited Proliferative Capacity of Exhausted CD8 T Cells Preservation of cKO CD8 T cell quantity during prolonged exposure to high levels of antigen prompted us to assess the epigenetic status of genes associated with the cell's proliferative potential. c-Myc has been shown to be essential for activationinduced metabolic reprogramming and antigen-driven proliferation of naive CD8 T cells (Wang et al., 2011) , and our data revealed that the Myc locus acquires an exhaustion-associated de novo DMR ( Figure 1I ). Loci-specific methylation analysis of the Myc DMR among naive, functional-memory, and exhausted WT virus-specific CD8 T cells confirmed that the Myc locus undergoes striking demethylation during the effector stage of the immune response, followed by remethylation during chronic antigen exposure ( Figure S5A ). In contrast, memory CD8 T cells retained their demethylated state ( Figure S5A ). To determine if this epigenetic program was coupled to changes in Myc-regulated expression programs, we measured the surface expression of CD98, a downstream metabolic target of c-Myc, in antigen-specific WT and cKO CD8 T cells during chronic or acute LCMV infection. Demethylation of the Myc DMR in WT effector antigen-specific CD8 T cells was coupled to upregulated CD98 expression ( Figure S5B ). Additionally, both WT and cKO memory CD8 T cells maintained elevated levels of CD98 expression ( Figure S5B ). In contrast, CD98 expression was downregulated on the exhausted WT cells but was retained at higher levels on cKO CD8 T cells during chronic infection ( Figure S5B ), indicating that the de novo methylation acquired during the development of T cell exhaustion is coupled to Myc-regulated protein expression.
To examine whether these programs were coupled to T cell proliferation, we stained virus-specific CD8 T cells for Ki67 at the effector and chronic stages of the immune response. At 8 dpi, the majority of both WT and cKO effector CD8 T cells expressed high levels of Ki67 ( Figure S5C ), but by 60 dpi, the proliferation of virus-specific WT CD8 T cells was substantially reduced. In contrast, antigen-specific and polyclonal virus-specific cKO CD8 T cells have significantly higher levels of Ki67 in both Tim-3 + and Tim-3 À subsets of PD-1 + cells ( Figures S5D-S5F ). These data suggest that the elevated quantity of cKO cells during persistent infection is in part coupled to their retained proliferative capacity.
CD8 T Cell-Intrinsic De Novo Programming Regulates Exhaustion
To determine whether the retained effector function and proliferative capacity of Dnmt3a-cKO CD8 T cells exposed to chronic stimulation are due to cell-intrinsic changes in DNA-methylation programming rather than extrinsic factors, we generated cKO transgenic P14 cells (transgenic CD8 T cells with a TCR specific to the gp33 epitope) and co-adoptively transferred congenically distinct WT and cKO P14 CD8 T cells into Rag1 KO mice. Use of the chimeric Rag1 KO mouse model enabled us to control for the influence of extrinsic factors such as other activated Gzmbexpressing immune cells-NK and CD4 T cells, undetected differences in viral titers, inflammatory microenvironment, and differences in the depletion of peripheral CD4 T cells among WT versus cKO mice. Chimeric Rag1 KO mice were infected with the chronic strain of LCMV, and the P14 cells were tracked longitudinally ( Figure 3A ). Both WT and cKO P14 cells underwent a similarly robust expansion during the effector stage of the immune response, but following this proliferative burst, WT P14 cells experienced a much greater degree of contraction relative to host-matched cKO P14 cells, resulting in an elevated frequency of cKO P14 cells that was maintained into the chronic stage of the immune response ( Figure 3B ). The selective preservation of cKO P14 cells during chronic infection was not only observed in the blood and spleen but also in peripheral nonlymphoid tissues, including the liver and lungs ( Figure 3C ). We (D) found that the cKO P14 cells retained an enhanced capacity to proliferate, higher Tcf1 expression, and heightened effector cytokine production ( Figures 3D and 3E ). Locus-specific DNAmethylation analysis of a post-effector-associated DMR (e.g., in the IFNg locus) and an effector-associated DMR (e.g., in the Tcf7 locus) further confirmed selective inhibition of de novo DNA-methylation programming in cKO P14 cells (Figures 3F and 3G) . These data confirm that the retained effector properties of cKO CD8 T cells are cell intrinsic and collectively suggest that Dnmt3a-mediated DNA-methylation programming is critical for establishing the major hallmarks of T cell exhaustion.
PD-1 Blockade Therapy Does Not Erase ExhaustionAssociated DNA-Methylation Programs in Rejuvenated T cells Our finding that exhaustion-associated DNA-methylation programs play a critical role in establishing a terminal-exhaustion fate prompted us to next ask whether PD-1 blockade-mediated rejuvenation of T cells results in erasure of these programs (Figure 4A) . To address this question, we treated chronically infected WT mice with anti-PD-L1, isolated the rejuvenated antigen-specific CD8 T cells, and assessed the methylation status of the exhaustion-associated DMRs ( Figure 4A ). As expected, PD-1 blockade treatment increased the quantity of gp33-specific and total polyclonal CD44 hi PD-1 + CD8 T cells in WT mice (Figure 4B) . Quite strikingly, we observed no change in the effector and post-effector de novo DNA-methylation programs despite T cell expansion ( Figures 4C and S2C) . Preservation of the de novo DNA-methylation programs at the IFNg, Myc, Tcf7, Ccr7, and Tbx21 loci in the rejuvenated WT CD8 T cells prompted us to more broadly assess the stability of DNA-methylation programming in all Dnmt3a-targeted genes. WGBS was performed on FACS-purified antigen-specific CD8 T cells from the spleens of the PD-1 blockade-treated and untreated WT mice ( Figure 4A ). Only 5,964 DMRs between the treated versus untreated WT CD8 T cells were detected among the WT exhausted and WT rejuvenated WGBS datasets. Among the 5,964 DMRs, only 84 were Dnmt3a-mediated programs, which accounts for less than 2% reprogramming of the total Dnmt3a-mediated exhaustion programs ( Figure 4D ). Notably, when we compared PD-1 blockade-associated DNA-methylation DMRs with the methylation profiles of functional-memory WT CD8 T cells, we found that <1% of these DMRs were present in the functional T cells ( Figure 4D ). Importantly, exhaustion-associated DNAmethylation programming across the IFNg, Myc, Tcf7, and Tbx21 loci were unchanged in rejuvenated WT CD8 T cells (Figures 4E and S2C) . These data illustrate how remarkably stable the exhaustion-associated DNA-methylation programs are. Given that PD-1 blockade does not erase exhaustion-associated methylation programs and that they play a causal role in restricting effector function, it raises the question of whether these specific epigenetic programs restrict the therapeutic response of PD-1 blockade treatment.
Inhibition of De Novo DNA-Methylation Programming Synergizes with PD-1 Blockade to Enhance Rejuvenation of CD8 T Cells
Maintenance of PD-1hi Dnmt3a cKO virus-specific CD8 T cells in an environment with viral loads comparable to chronically infected WT mice provided a unique opportunity to test whether Dnmt3a-mediated de novo DNA methylation restricts the ability of cells to respond to PD-1 blockade therapy. Chronically infected WT and Dnmt3a cKO mice were treated with anti-PD-L1 for 2 weeks, and the antigen-specific T cell response was measured ( Figure 5A ). Quite strikingly, the cKO virus-specific CD8 T cells increased in frequency and quantity during PD-1 blockade to a significantly greater degree compared to WT virus-specific CD8 T cells. The expanded population of cKO T cells was observed not only in the spleen ( Figures 5B, S6A , and S6B) but also in non-lymphoid tissues ( Figures 5C, 5D , S6C, and S6D). Notably, gp33-specific and np396-specific CD8 T cells, which are known to be less responsive to PD-1 blockade relative to gp276-specific CD8 T cells, underwent a synergistic expansion after PD-1 blockade treatment in cKO mice ( Figures 5B, S6C , and S6E). Consistent with our observation that Dnmt3a-deficient CD8 T cells resist terminal differentiation, the expanded virus-specific cKO CD8 T cells retained lower levels of Tim-3 and Eomes and a higher level of T-bet after PD-1 blockade treatment ( Figures S6A and S6B ). These data demonstrate that de novo DNA-methylation programs restrict the ability of exhausted T cells to respond to PD-1 blockade therapy. Because we observed a striking response across multiple LCMV epitope-specific CD8 T cell populations in cKO mice, we next proceeded to determine whether the expanded pool of cKO cells maintained their T cell clonal diversity. GP33-specific CD8 T cells were single-cell sorted from the blood of chronically infected WT and cKO mice before and after PD-L1 blockade, and the TCR b chain of the individual cells was sequenced. Interestingly, rejuvenated WT CD8 T cells displayed a reduced TCR repertoire diversity among the expanded gp33-specific T cells, whereas the TCR repertoire diversity of gp33-specific cKO CD8 T cells was maintained after PD-1 blockade treatment ( Figures  5E and S6G ). These data suggest that exhaustion-associated DNA-methylation programming restricts the clonal breadth of cells that can proliferate in response to PD-1 blockade therapy.
We next assessed the function of the PD-L1 blockadeexpanded population of antigen-specific cKO CD8 T cells by measuring their ability to recall effector cytokines after peptide stimulation. Indeed, the expanded population of LCMV-specific cKO CD8 T cells retained a heightened capacity to produce IFNg and IL-2 (Figures 5F, S6H, and S6I). Given that PD-1 blockade in the cKO mice resulted in expansion of an extensive repertoire of LCMV-specific CD8 T cells that retained effector properties, we next proceeded to determine whether the enhanced therapeutic response impacted the viral load. Strikingly, anti-PD-L1 treatment resulted in a significant reduction in the viral burden in multiple tissues in cKO mice compared to that in anti-PD-L1-treated WT mice ( Figure 5G ). These data collectively serve as a proof of principle that therapeutic approaches designed to erase or block exhaustion-associated DNA-methylation programs may synergize with ICB therapy and enhance the therapeutic response.
DNA-Demethylating-Agent Treatment Prior to PD-1 Blockade Enhances the Reinvigoration Potential of Exhausted CD8 T Cells Our finding that de novo DNA-methylation programming is causal in reinforcing the development of T cell exhaustion and establishes a stable cell-intrinsic barrier to PD-1 blockade-mediated rejuvenation of T cells prompted us to ask whether therapeutic use of DNA-demethylating agents prior to PD-1 blockade treatment could enhance rejuvenation of WT exhausted CD8 T cells. WT mice chronically infected with LCMV were treated with a low dose of the standard DNA-demethylating agent 5-aza-2 0 -deoxycytidine (decitabine ''DAC'') for 2 weeks followed by PD-1 blockade ( Figure 6A ). Longitudinal analysis of virus-specific CD8 T cell quantity in the peripheral blood of chronically infected mice revealed a synergistic expansion of gp33-specific T cells in treated mice that received DAC prior to PD-1 blockade therapy compared to those receiving monotherapy ( Figures 6B  and 6C ). Importantly, this increase in antigen-specific and the total polyclonal virus-specific CD8 T cell frequencies was also observed in the spleen, lungs, and liver of chronically infected WT mice receiving sequential combination therapy ( Figures 6D,  6F , 6G, S7A, and S7B). Notably, concurrent treatment of DAC with PD-1 blockade did not enhance rejuvenation of WT exhausted T cells (data not shown). The striking expansion of virus-specific T cells observed in both lymphoid and nonlymphoid tissues of sequentially treated mice suggests that DNA-demethylating-agent treatment may synergize with PD-1 blockade to enhance the rejuvenation.
To determine whether the elevated frequencies of rejuvenated WT CD8 T cells that result from sequential DAC and PD-1 blockade treatment are coupled to enhanced proliferation, we measured Ki67 expression in antigen-specific and polyclonal virus-specific CD8 T cells in chronically infected mice. Interestingly, DAC treatment significantly increased the proliferative capacity of virus-specific CD8 T cells ( Figures 6E, 6H , S7C, and S7D). Furthermore, combination treatment results in a greater number of cells that could recall the expression of the effector cytokine ( Figures S7E-S7G ), albeit not quite as effective as genetic deletion of the DNA methyltransferase. While the antitumor effect of DNA-demethylating agents is commonly attributed to its direct cytotoxicity or immunoregulating influence on tumor cells or microenvironment (Chiappinelli et al., 2016; Li et al., 2014) , our data suggest that therapeutic DNA demethylation may also function by reversing exhaustion-associated de novo methylation programs in CD8 T cells, consequently enhancing the T cell's ability to expand during ICB therapy.
Tumor-Infiltrating CD8 T Cells Acquire ExhaustionAssociated De Novo DNA-Methylation Programs Recent advances in ICB therapies have provided a major breakthrough in the treatment of various cancers. Therefore, we sought to determine whether our findings, made using a model of chronic viral infection, extended to a tumor setting. To assess the DNA-methylation status of tumor-associated CD8 T cells, we generated tumor-bearing mice utilizing the well-established murine Tramp-C2 tumor model. This model is characterized by a relatively slow tumor growth that results in prolonged stimulation of T cells (Curran and Allison, 2009 ). After >45 days post Tramp-C2 cell inoculation, tumor-infiltrating CD8 T cells (TILs) were characterized ( Figure 7A ). Phenotypic analysis of tumor-specific (Spas1 tetramer+) CD8 T cells demonstrated that they exhibited characteristics of persistent antigen exposure, including coexpression of PD-1 and Tim-3 ( Figure 7B ). To determine whether exhaustion-associated DNA-methylation programs are acquired in phenotypically activated CD8+ TILs, we FACS purified the PD-1hi Tim3+ CD8+ TILs and measured the DNA-methylation status of Tcf7, Ccr7, Myc, and IFNg DMRs ( Figure 7C ). Additionally, we FACS purified tumor-matched PD-1lo CD8+ TILs to determine whether the exhaustion-associated DMRs were (legend continued on next page) specifically acquired in activated TILs. Similar to exhausted LCMV-specific CD8 T cells, the de novo DMRs at the Tcf7, Ccr7, Myc, and IFNg loci in PD-1hi TILs were heavily methylated, whereas PD-1lo TILs retained demethylated Ccr7 and Tcf7 loci ( Figures 7D, 7E , and S7H). Select methylation of the Tcf7 and Ccr7 loci among the PD-1hi TILs demonstrates that the cells underwent de novo programming at these loci and further indicates that the extensive methylation of the Myc and IFNg DMRs in the PD-1hi TILs are also de novo programs. These results demonstrate that tumor-infiltrating CD8 T cells acquire de novo DNAmethylation programming associated with reinforcement of T cell exhaustion. Given the critical role exhaustion-associated DNA methylation plays in regulating ICB-responsiveness during chronic virus infection, we sought to further assess the impact these programs have on TIL-rejuvenation during PD-1 blockade. The Tramp-C2 tumor model has been previously shown to be refractory to single PD-1/PD-L1 blockade therapy (Yu et al., 2012 ); therefore, we tested whether primary DAC treatment could enhance rejuvenation of CD8 TILs after PD-L1 blockade. Sequential DAC and PD-L1 blockade treatments were initiated more than 4 weeks and 6 weeks, respectively, after tumor inoculation ( Figure 7F ). Interestingly, we found that DAC treatment was able to induce proliferation of both polyclonal (PD-1hi) and antigen-specific (Spas-1 tetramer+) tumor-infiltrating CD8 T cells after PD-L1 blockade treatment ( Figure 7G) . Importantly, the enhanced proliferation of tumor-specific CD8 T cells was coupled to significant control of tumor growth ( Figures 7H and S7I ). These data suggest that administration of DNA-demethylating agents prior to ICB therapy may enhance reinvigoration of antitumor CD8 T cells, providing a rationale for therapeutic strategies that combine epigenetic reprogramming and ICB.
DISCUSSION
Reinvigoration of exhausted CD8 T cells by PD-1 blockade therapy has emerged as one of the most promising frontiers to treat individuals with chronic infections or cancer. However, the stability of exhaustion-specific gene-expression programs suggests that a cell-intrinsic mechanism(s) may restrict the capacity and durability of PD-1 blockade-mediated T cell rejuvenation. We and others have demonstrated that changes in epigenetic programming are coupled to transcriptional reprogramming during CD8 T cell effector and memory differentiation (Crompton et al., 2016; Russ et al., 2014; Scharer et al., 2013; Youngblood et al., 2011 ). Yet, whether these reprogramming events play a direct role in regulating the effector properties in functional and exhausted CD8 T cells has remained unclear. Here, we show that progressive de novo DNA-methylation programming is critical for establishing T cell exhaustion. Such DNA-methylation programming reinforces the repression of key genes involved in effector function, proliferation, metabolic activity, and tissue homing in exhausted T cells. We also demonstrate that these long-lived, exhaustion-associated epigenetic programs serve as a major cell-intrinsic barrier limiting the rejuvenation of antigen-specific CD8 T cells during PD-1 blockade therapy. Our findings highlight epigenetic programs among exhausted T cells as a potential mechanism to explain PD-1 blockade therapeutic failures.
Recent efforts to better understand the mechanism of action for ICB therapy found that the Cxcr5+ subset of PD-1+ T cells remain responsive to PD-1 blockade therapy, while T cells that express both PD-1 and Tim-3 and that lack Cxcr5 expression are less responsive to PD-1 blockade therapy (Im et al., 2016; Wherry, 2011) . Importantly, when we compared our cKO and WT exhausted CD8 T cell gene expression datasets ( Figures  S3D-S3F ) with the recently published gene expression data of Cxcr5+ Tim-3
Àve (PD-1 blockade-responsive) versus Cxcr5
Àve Tim-3+ (PD-1 blockade-nonresponsive) subsets of exhausted WT CD8 T cells (Im et al., 2016) , we found a significant correlation among gene expression patterns of cKO CD8 T cells and the PD-1 blockade-responsive subset of WT cells ( Figure S3G ), further highlighting the role de novo DNA methylation plays in regulating PD-1 blockade-responsiveness. These data indicate that progressive development of less-differentiated CD8 T cells into terminally differentiated exhausted CD8 T cells is coupled to the acquisition of transcriptionally repressive DNA-methylation programs. Moreover, once established, such epigenetic programs restrict the cell's reinvigoration potential during PD-1 blockade therapy. While a durable clinical response has been generated in some patients that experience ICB-mediated reinvigoration of T cells, new evidence suggests that T cell rejuvenation may be transient. In a recent clinical trial utilizing ICB for melanoma treatment, about one-third of patients who initially responded to PD-1 blockade experienced tumor relapse (Ribas et al., 2016) . Through efforts to better understand the stable nature of exhaustion-associated transcriptional states, it was recently discovered that the short-lived reinvigoration of T cells during PD-1 blockade therapy was associated with preservation of the chromatin landscape (Pauken et al., 2016) . The results presented in our current study provide mechanistic insight into the heritable maintenance of exhaustion gene expression program during ICB and how this may leave patients vulnerable to tumor relapse (Ghoneim et al., 2016; Sharma and Allison, 2015b) .
DNA-methylation programming in fully differentiated cells is often thought to be irreversible owing to the fact that DNA methylation can be propagated during DNA replication through a mechanism of maintenance methylation. Yet the recent discovery that cytosine methylation can be erased through a mechanism of TET-mediated hydroxylation has generated great interest in determining whether this mechanism can be exploited (F) Experimental setup of sequential decitabine and anti-PD-L1 treatment of TRAMP-C2 tumor-bearing mice starting at R1 month post-inoculation. (G) Representative FACS analysis and summary graphs of Ki67 levels among PD-1hi CD8+ TILs and tumor antigen-specific (Spas1+) TILs after mono PD-1 blockade or sequentially combined decitabine and anti-PD-L1 treatments. (H) Longitudinal measurement of tumor growth in WT mice receiving mono anti-PD-L1 (red) or sequentially combined decitabine and anti-PD-L1 (blue) treatments. Summary graph of normalized tumor volume after mono anti-PD-L1 (red) or combined decitabine and anti-PD-L1 (blue) treatments. N = 3-5 mice per group of two independent experiments. Error bars indicate SEM.
to de-differentiate fate-committed cells (Pastor et al., 2013) , specifically exhausted T cells during ICB therapy. In addition to exploiting natural mechanisms of epigenetic reversal, it may be possible to directly reverse epigenetic modifications with existing chemotherapeutics (Chiappinelli et al., 2016; Roulois et al., 2015; Wang et al., 2015) . FDA-approved DNA demethylating agents, such as decitabine, may provide a means to modify exhaustion-associated DNA methylation programs that restrict ICB-responsiveness. Consistent with our results, two recent reports have highlighted the ability of DNA-demethylating agents to enhance CTLA-4 blockade-mediated T cell responses (Chiappinelli et al., 2016; Wang et al., 2015) . In these studies, the effect of DNA demethylation was largely assigned to changes in expression of endogenous retrovirus dsRNA in the tumor, which in turn triggered a type I IFN immune response (Chiappinelli et al., 2016) . Our data suggest that decitabine not only modifies the tumor cells but may also have a direct effect on antigen-specific CD8 T cells. In conclusion, our study highlights the critical role de novo DNA methylation plays in establishing the ICB-nonresponsive state of T cell exhaustion and reveals the potential benefit of therapeutic strategies that combine ICB with approaches that reverse or inhibit T cell-intrinsic exhaustion-associated epigenetic programs.
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Anti-mouse T-bet (clone 4B10) BioLegend Cat#644806
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice and Viral Infections WT C57BL/6 mice were purchased from Jackson Laboratory. Dnmt3a cKO mice were generated by crossing floxed Dnmt3a mice with mice expressing a Granzyme b-driven recombinase transgene. Equal numbers of male and female 6-8 week old WT and cKO mice were used and littermates of the same sex were randomly assigned to experimental groups. For chronic infection, WT and cKO mice were treated with 0.75 mg GK1.5 antibody (Harlan Bioproducts) 2 days prior to and on the day of infection to deplete CD4 T cells (Ha et al., 2008) . CD4-deficient mice were then infected with the LCMV clone 13 (2 3 10 6 pfu, i.v.). Serum and tissue virus titers were determined by plaque assay as previously described (Matloubian et al., 1990) . For acute infection, equal numbers of male and female 6-8 week old WT and cKO mice were infected with the Armstrong strain of LCMV (2 3 10 5 pfu, i.p.) without CD4 T cell depletion. All mice were housed in specific pathogen free conditions prior to use. Prior to the described studies, mice were drug naive and determined to be healthy by the veterinary staff. All protocols were approved by the St Jude Children's Research Hospital Institutional Animal Care and use Committee, and all mice were handled per their guidelines.
TRAMP-C2 Tumor Mouse Model TRAMP-C2 prostate adenocarcinoma cell line was purchased as ATCC CRL-2731Ô and grown as previously described (Foster et al., 1997) . 1310 6 tumor cells were injected s.c in the right flank of syngeneic 6-8 week old male WT C57BL/6 mice and tumor growth was monitored. Male recipients for tumor growth experiments were used due to the origin of the TRAMP C2 tumor line. All mice were housed in specific pathogen free conditions prior to use. All protocols were approved by the St Jude Children's Research Hospital Institutional Animal Care and use Committee, and all mice were handled per their guidelines.
METHOD DETAILS
In Vivo Decitabine and PD-1 Blockade Treatment Under chronic LCMV infection setting Equal numbers of male and female 6-8 week old WT C57BL/6 mice were chronically infected with LCMV clone 13 after CD4 T cell depletion as described above. Mice were randomly assigned to experimental groups. At R 33 dpi mice were i.p. injected with vehicle or decitabine (Sigma-Aldrich; 1.2 mg/kg) dissolved in sterile PBS every 3 days for 2 weeks, followed by PBS or anti-PD-L1 treatment (BioXcell; 200 mg) every 3 days for 2 weeks. Under tumor setting TRAMP-C2 tumor-bearing male C57BL/6 mice (as described above) were randomly assigned to experimental groups. After R 30 post-inoculation, tumor-bearing mice were i.p injected with vehicle or decitabine treatment for 2 weeks as described in the chronic LCMV infection model, followed by anti-PD-L1 treatment (BioXcell; 200 mg) every 3 days for 2 weeks. At indicated time points, tumors were harvested and tumor-infiltrating CD8 T cells were characterized.
Analysis of Antigen-Specific T Cell Function and Phenotype
Antigen-specific CD8 T cells were identified or purified by FACS using fluorescently labeled H-2D b tetramers bound to LCMV peptides. LCMV and tumor-specific Spas-1 monomers were obtained from the Yerkes NIH tetramer core facility. Phenotypic analysis of the cells was performed using the following fluorescently labeled antibodies: CD8, CD44, CD62L, PD-1, Tim-3, and CD98 (BioLegend), as previously described (Wang et al., 2011; Wherry et al., 2003) . The total pool of virus-specific CD8 T cells was defined as CD44 hi PD-1 + CD8 T cells. Ki67, Tcf1, T-bet, and Eomes intracellular staining was performed using the eBioscience ICS-staining protocol and fluorescently labeled antibodies against T-bet (clone 4B10; BioLegend), Eomes (clone Dan11mag; eBioscience), Tcf1 (clone C63D9; Cell Signaling), and Ki67 (clone SolA15; eBioscience). Ex vivo stimulation of antigen-specific splenocytes was performed using gp33 peptide, as previously described (Youngblood et al., 2011) . Intracellular staining for IFNg, IL-2, and Granzyme b was performed with fluorescently labeled antibody clones XMG1.2, JES6-5h4, and GB11, respectively (all from BioLegend) and by using BD Cytofix/Cytoperm (BD Biosciences) per the manufacturer's instructions. Cell death frequency was calculated using Ghost Dye Violet 510 viability dye (Tonbo Biosciences) to determine the frequency of live cells in the total lymphocyte-singlet gate.
Genome-Wide and Loci-Specific Methylation Analysis
We sorted viable naive (CD44 low CD62L + ) and tetramer + (gp33 + CD44 hi ) CD8 T cells from the splenocytes of acutely or chronically infected WT and cKO mice. For loci-specific methylation analysis of TILs, viable PD-1hi and PD-1low subsets of TILs were sorted from TRAMP-C2 tumors at > 45 days post-inoculation. DNA was isolated from the FACS-purified naive, antigen-specific CD8 T cells, and TILs by using the QIAGEN DNeasy kit. Genomic DNA was bisulfite treated using the EZ DNA methylation kit (Zymo Research). Bisulfite-induced deamination of cytosine allows for sequencing-based discrimination of methylated versus non-methylated cytosine (Trinh et al., 2001) .
To perform genome-wide methylation analysis, a bisulfite-modified DNA-sequencing library was generated according to Illumina's instructions accompanying the TruSeq DNA Methylation Kit (Part# EGMK81312). Briefly, Bisulfite converted DNA was annealed with random hexamer with tagging sequence. DNA copy was synthesized using TruSeq DNA Methyl Polymerase. Then Exonuclease I was used to digest excess random primer. The 3 0 ends of the strands are then selectively tagged with a second specific sequence tag to generate di-tagged DNA using DNA polymerase. The di-tagged DNA with known sequence tags at both ends was cleaned up by the AMPureXP Beads. The dsDNA library was generated by PCR amplification with Illumina primers for 10 cycles and library fragments of $350 bp (insert plus adaptor and PCR primer sequences). The library was purified by the AMPureXP Beads. The purified DNA was captured on an Illumina flow cell for cluster generation. Libraries were sequenced on the HiSeq 2500 following the manufacturer's protocols.
To perform loci-specific methylation analysis, the bisulfite-modified DNA was PCR amplified with locus-specific primers (Table S1 ). The PCR amplicon was cloned into the pGEM-T TA cloning vector (Promega) and then transformed into XL10-Gold ultracompetent E. coli bacteria (Stratagene). Individual bacterial colonies were grown overnight over Luria-Bertani (LB) agar containing ampicillin (100 mg/L), X-gal (80 mg/L), and IPTG (20 mM). White colonies were selected and subcultured into LB broth with ampicillin (100 mg/L) overnight; the cloning vector was purified; and the genomic insert was sequenced.
Microarray gene expression analysis
Microarray gene expression analysis was performed in FACS-purified naive and LCMV-specific CD8 T cells from chronically infected WT and cKO mice at 35 dpi. The microarray data were measured by Affymetrix Mouse Gene 2.0 ST arrays and were processed with Partek Genomics Suite 6.6 by the RMA method. To compare gene expression patterns of WT and cKO CD8 T cells to those of CXCR5+ Tim-3-and CXCR5-Tim-3+ subsets of exhausted WT CD8 T cells published in (Im et al., 2016) , we downloaded their normalized microarray data from GSE84105 and compared Tim-3+ with CXCR5+. Genes that were in GSE84105 but were not measured in our array were removed. We identified 524 upregulated genes in Tim-3+ and 667 downregulated genes in Tim-3+ using fdr % 0.05 and log2 fold at least 1 as the cutoff. The enrichment of the 2 gene sets in our KO versus WT comparison was done using CAMERA. The differential gene expression analysis and CAMERA analysis were done using LIMMA package 3.24.5 in Bioconductor.
TCR Repertoire Analysis LCMV gp33-specific T cells were stained with specific tetramer, resuspended in freshly made sort buffer (PBS containing 0.1% BSA (GIBCO) and 200 U RNAsin/ml (Promega)) and filtered prior to sorting. Several hundreds of tetramer-positive T cells were single cell sorted into the wells of a 96-well PCR plates (Eppendorf) that had been preloaded with 2.5 ul of reverse transcription mixture (0.5 mL 5X iScript reaction mix, 0.5 mL iScript reverse transcriptase (Biorad), and 0.1% Triton X-100 (Sigma-Aldrich)) using a iCyt Synergy cell sorter (Sony). The parameters used for sorting are: Multi-drop sort OFF, Multi-drop exclude OFF, Division 10, Center sort%: 90. The last two columns of the plate were left unsorted to serve as negative controls for the PCR. Following sorting, the plates were sealed immediately using plate sealer film (MicroAmp, Applied Biosystems) and centrifuged at 500 g for 3 min prior to storing at À80 C until reverse transcription and PCR.
The CDR3b region of individual cells were amplified and sequenced using a nested, single-cell, multiplex PCR approach (Dash et al., 2011) . Briefly, cDNA was synthesized directly from single cells as per the manufacturer's instructions with minor modifications. The cDNA synthesis was followed by two rounds of PCR with a Taq polymerase-based PCR kit (QIAGEN) and a cocktail of TCR b specific primers to amplify the CDR3b transcripts from each cell in a 25 mL reaction volume. The PCR products were visualized on a 2% agarose gel, then purified using exonuclease/Shrimp alkaline phosphatase enzymes (Dash et al., 2015) and sequenced using TRBC reverse primer, using an ABI Big Dye sequencer (Applied Biosystem) at the Hartwell Center of St. Jude Children's Research Hospital.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis N = 3-5 per group of at least two independent experiments. Statistical analysis was performed using Prism 6 (GraphPad) software and Statistical significance was determined if P value is less than 0.05. Comparisons were made using Mann-Whitney U test (for pairwise comparisons in Figures 1-4 , 5B, 5F, 6, and 7); ANOVA test (for multiple comparisons in Figure 5G ); unpaired t test with Welch's correction (for CpG methylation comparisons); or parametric two-tailed paired t test for paired analysis of Simpson's diversity index of TCR repertoire data.
Whole-Genome Bisulfite DNA Sequencing Analysis WGBS data were aligned to the mm10 mouse genome using BSMAP2.74. CpG methylation was performed using model-based analysis of bisulfite sequencing (Wu et al., 2015) . Differentially methylated regions (DMRs) were identified using Bioconductor package DSS and custom R scripts with a threshold of 20% change in methylation ratio and p value % 0.01 as a cutoff. The minimum length for DMR is 50 bps and the minimum number of CpG sites for DMR is 3. DMRs were annotated using mm10 RefSeq in the following order: promoter from À1kb to 1kb of TSS (transcription start site), 5 0 distal from À50kb to À1 kb of TSS, downstream of À1 kb to 1kb of TTS (transcription termination site), 3 0 distal from 1kb to 50 kb of TTS, exon, intron, and any other genomic regions were defined as intergenic. The M-value, the measurement of CpG methylation status, was used for principle component analysis (PCA) and dendrogram. For the dendrogram, complete linkage method with Euclidean distance measurement based on M-value was used. The M-value is calculated as the log2 ratio of the number of methylated reads versus unmethylated reads. To avoid zero read count, 0.5 is added to the read count. The top 3000 most variable CpG sites with > 5X coverage were selected to do the PCA and clustering analysis.
Simpson's Diversity Index Analysis TCR repertoire sequencing data were analyzed using a custom-built macro-enabled excel sheet in conjunction with an IMGT web interface to derive CDR3b nucleotide and amino acid sequences with corresponding TRBV-TRBJ family usage (Dash et al., 2015; Lefranc et al., 2009 ). Simpson's Diversity Index (D) was calculated on the population from each mouse as previously described (Thomas et al., 2013) , with D = S i [(n i (n i À 1))/ (N(N À 1)) ], where n i is the number of sequences in the ith clonotype and N is the total number of sequences in the whole population.
DATA AND SOFTWARE AVAILABILITY
The accession number for the WGBS datasets and microarray data reported in this paper are GEO: GSE99450 and GEO: GSE99449, respectively. (F) Scatterplot showing statistically significant inverse relationship between gene expression changes and DNA methylation changes in WT exhausted cells. y axis shows log2 fold change between WT versus cKO antigen-specific CD8 T cells from chronically infected mice at R 35 dpi, and x axis shows differential DNA methylation changes in WT versus cKO antigen-specific CD8 T cells from chronically infected mice at 35 dpi with 20% cutoff (R0.2). (G) Graph-based visualization of statistical enrichment between differentially expressed genes in CXCR5+ subset versus Tim-3+ subset of exhausted LCMVspecific WT CD8 T cells (using microarray data deposited in GSE84105, with FDR % 0.05 and log2 fold change R 1 as the cutoff) and gene expression patterns in our microarray data of cKO versus WT LCMV-specific CD8 T cells in chronically infected mice. The enrichment of the 2 gene sets in our KO versus WT comparison was done using CAMERA. (legend continued on next page)
